| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 63,567 | 70,433 | ||
| Accounts receivable | 0 | 0 | ||
| German research and development tax credit receivable | 2,216 | 1,978 | ||
| Prepaid expenses and other current assets | 1,154 | 1,336 | ||
| Total current assets | 66,937 | 73,747 | ||
| Total assets | 66,937 | 73,747 | ||
| Accounts payable | 3,481 | 4,557 | ||
| Derivative liabilities - contingent value right agreement | 2,216 | 1,978 | ||
| Accrued expenses and other current liabilities | 4,615 | 3,081 | ||
| Total current liabilities | 10,312 | 9,616 | ||
| Royalty agreement liability | 16,021 | 14,511 | ||
| Derivative liabilities - royalty agreement | 1,922 | 1,840 | ||
| Total liabilities | 28,255 | 25,967 | ||
| Common stock, 0.001 par value 200,000,000 shares authorized 11,088,329 and 11,012,105 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 11 | 11 | ||
| Additional paid-in capital | 161,303 | 159,271 | ||
| Accumulated other comprehensive (loss) income | 104 | -111 | ||
| Accumulated deficit | -122,736 | -111,391 | ||
| Total stockholders' equity | 38,682 | 47,780 | ||
| Total liabilities and stockholders' equity | 66,937 | 73,747 | ||
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)